Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Microsoft Taps AWS to Support GitHub Amid AI Coding Boom 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
SoftBank Shares Drop as OpenAI Losses and Rising Costs Spark Investor Concerns 
BHP Shares Fall as Jansen Potash Project Costs Surge 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Chinese Social Media Giant Xiaohongshu Eyes Hong Kong IPO at Over $70 Billion Valuation 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
Qantas Nears Launch of World’s Longest Non-Stop Flights to London and New York 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
NEW YORK, Nov. 30, 2015 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Nevada on behalf of investors who purchased Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) securities between May 7, 2015 and October 23, 2015.
Click here to learn about the case: http://docs.wongesq.com/SPPI-Info-Request-Form-1012. There is no cost or obligation to you.
The complaint alleges that Spectrum Pharmaceuticals violated federal securities laws by disseminating materially false and misleading information and failing to disclose material facts, causing the stock to trade at artificially inflated prices.
On October 23, 2015, Spectrum announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) in response to its New Drug Application seeking clearance for Evomela, indicating that the FDA cannot approve the application in its present form. Upon this news, shares of Spectrum Pharmaceuticals fell more than 20% on intraday trading.
If you suffered a loss in Spectrum Pharmaceuticals you have until January 4, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/SPPI-Info-Request-Form-1012.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
